
10x Genomics is a leader in the field of genomic analysis, offering a suite of innovative products and tools that enable researchers to unlock the secrets of the genome. Their flagship product, the Chromium System, is a key component of their offerings.
The Chromium System is a powerful tool for single-cell analysis, allowing researchers to study individual cells in depth. This is made possible by its unique ability to capture and analyze the transcriptome of each cell.
10x Genomics also offers a range of transcriptomic tools, including the GemCode System and the Visium Platform. These tools provide researchers with the ability to analyze gene expression at the single-cell level, revealing new insights into cellular biology.
You might enjoy: 3x 2 10x 2
You might enjoy: Simon Segars
Products and Solutions
At Single Cell Discoveries, we offer a range of 10x Genomics solutions that cater to different needs.
Our 10x Genomics Single Cell Gene Expression (3') is a great starting point for researchers.
We also have Single Cell Gene Expression Flex, which provides flexibility in data analysis.
Additionally, we offer Single Cell Immune Profiling (5'), which is ideal for immune-related research.
And for those who want to explore cell surface protein data, we have CITE-seq.
For your interest: Buy Scoe 10x
Chromium iX

The 10x Genomics Chromium iX is a more cost-effective option compared to the original Chromium Controller.
It has lower throughput, which means it can process fewer cells at a time, typically in the range of 1,000 to 10,000 cells.
This makes it a great choice for researchers who need to run moderate-throughput assays on a budget.
The Chromium iX is also upgradable to a "full-range" 10x Chromium X with a simple software update.
This means you can future-proof your investment and take advantage of new features and capabilities as they become available.
Solutions
We offer a range of solutions for your genetic expression needs.
Our team at Single Cell Discoveries has expertise in 10x Genomics solutions, including Single Cell Gene Expression (3') and Single Cell Gene Expression Flex.
These solutions allow for the analysis of gene expression data, which can be crucial for understanding cellular behavior.
We also offer Single Cell Immune Profiling (5') and CITE-seq, which includes cell surface protein data.
These solutions can be useful for researchers looking to gain a deeper understanding of immune cell function.
Find out more about our 10x Genomics services in the 10x Information Guide.
On a similar theme: Better Online Solutions
Diagnostic Substances

Diagnostic Substances are a crucial part of the medical industry, helping doctors diagnose and treat various diseases.
10X Genomics, Inc. is a leading company in this field, with a market capitalization of $1.53 billion.
Their stock has seen significant growth, with a 5-day change of +8.97% and a 1-year change of +12.36%.
However, their stock price has also experienced a 3-year change of -11.76% and a 47.98% decrease in market capitalization over the same period.
BIOMÉRIEUX, on the other hand, has maintained a stable stock price with a 5-day change of 0.00%.
GUARDANT HEALTH, INC. has seen impressive growth, with a 5-day change of +1.94% and a 1-year change of +8.04%.
CARIS LIFE SCIENCES, INC. has also experienced growth, with a 5-day change of +5.39% and a 1-year change of +1.60%.
However, their stock price has not been consistently stable over the past three years.
Here's a breakdown of the stock prices of these companies over the past 5 days, 1 year, and 3 years:
The average stock price change over the past 5 days, 1 year, and 3 years is +1.16%, +1.04%, and +66.66% respectively.
Additional reading: Golden 1 Credit Union
Zooming In on TXG
10x Genomics's shares are extremely volatile, with 47 moves greater than 5% over the last year. This volatility has led to some significant price swings, making it a stock to keep a close eye on.
In the past year, the stock has had some notable moves, including a 3.1% drop just one day ago due to market-wide caution ahead of a key speech by Federal Reserve Chair Jerome Powell. The upcoming Jackson Hole symposium was a major factor in this caution, with traders anxiously awaiting Powell's speech for guidance on interest rates.
10x Genomics is currently trading at $14.16 per share, which is 39.7% below its 52-week high of $23.49 from August 2024. This significant drop is a reminder that even the most promising stocks can experience downturns.
Investors who bought $1,000 worth of 10x Genomics's shares 5 years ago would now be looking at an investment worth $133.75, a significant decrease in value. This highlights the importance of doing thorough research and considering long-term growth potential before investing in a stock.
Data Analysis

10x Genomics provides a comprehensive data analysis platform that enables researchers to extract insights from their genomic data. This platform is built on top of their Chromium and Visium products.
Their data analysis tools allow for the identification of cell types and subpopulations, as well as the quantification of gene expression. This is made possible by the use of their proprietary algorithms and machine learning techniques.
By leveraging the power of their data analysis platform, researchers can gain a deeper understanding of complex biological systems and identify new targets for therapy.
A unique perspective: Aster Data Systems
Choosing the Right Transcriptomic Approach
Choosing the right transcriptomic approach can be overwhelming, but it's essential to consider the type of sample and research question you're trying to answer. Bulk transcriptomics is a good starting point for many studies, but it can't provide the level of detail that single-cell transcriptomics offers.
Single-cell transcriptomics, on the other hand, allows you to analyze individual cells, providing a more nuanced understanding of gene expression. This approach is particularly useful for understanding cellular heterogeneity and identifying rare cell populations.

The 10x Genomics Chromium System is a powerful tool for single-cell transcriptomics, capable of encapsulating hundreds to tens of thousands of cells into uniquely addressable partitions. This system is compatible with fresh, frozen, and methanol-fixed samples, making it a versatile option for various research applications.
Here are some key considerations for choosing between bulk and single-cell transcriptomics:
Ultimately, the choice between bulk and single-cell transcriptomics depends on your research goals and the type of sample you're working with. If you're looking for a more detailed understanding of gene expression, single-cell transcriptomics may be the better choice. However, if you're working with limited resources or need to analyze a large number of samples, bulk transcriptomics may be a more feasible option.
Data Science
As a data analyst, I'm always excited to dive into new technologies that can help us better understand the world around us. One such technology is gene sequencing, which has revolutionized the field of data science.
10x Genomics, Inc. is a leading biotechnology company that designs and manufactures gene sequencing technology used in scientific research. They were founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin Ness.
Their technology has enabled researchers to analyze vast amounts of genetic data, which has led to numerous breakthroughs in fields like medicine and genomics. With the ability to sequence entire genomes, researchers can now identify genetic variations that contribute to diseases.
10x Genomics has seen significant growth in recent years, with revenue reaching US$611 million in 2024. However, the company has also faced challenges, with an operating income of US$−195 million in 2024 and a net income of US$−183 million.
Despite these challenges, 10x Genomics remains a major player in the gene sequencing market, with over 1,306 employees working on their technology. Their website, 10xgenomics.com, provides a wealth of information on their products and services.
Industry and Market
10x Genomics has established itself as a leader in the field of genomics, with a focus on spatial genomics and single-cell analysis. The company's products are used in a variety of applications, including cancer research and immunology.

The company's industry presence is significant, with a strong market share in the genomics tools market. 10x Genomics' products are used in over 1,000 research institutions worldwide.
The company's technology has been used to publish over 1,000 research papers, with many more in progress. This demonstrates the impact of 10x Genomics' technology on the scientific community.
Additional reading: Lam Research
Composition of the Board of Directors
The composition of the Board of Directors for 10x Genomics, Inc. is comprised of experienced individuals with diverse backgrounds and expertise.
Ben Hindson, a 50-year-old Director/Board Member, has been part of the board since 2012. Serge Saxonov, also a 48-year-old Director/Board Member, shares the same joining date.
John Stuelpnagel, the Chairman, brings a wealth of experience to the table as a 67-year-old Director/Board Member since 2013.
The board has also seen recent additions, including Sridhar Kosaraju, a 47-year-old Director/Board Member who joined in 2019, and Shehnaaz Suliman, a 53-year-old Director/Board Member who also joined in 2019.
Additional reading: Old National Bancorp First Midwest Merger
Other notable board members include Kim Popovits, a 66-year-old Director/Board Member since 2020, Alan Mateo, a 63-year-old Director/Board Member since 2024, and Sarah Teichmann, a 49-year-old Director/Board Member since 2024.
Here is a list of the Board of Directors with their respective titles and ages:
- Ben Hindson, Director/Board Member, 50
- Serge Saxonov, Director/Board Member, 48
- John Stuelpnagel, Chairman, 67
- Sridhar Kosaraju, Director/Board Member, 47
- Shehnaaz Suliman, Director/Board Member, 53
- Kim Popovits, Director/Board Member, 66
- Alan Mateo, Director/Board Member, 63
- Sarah Teichmann, Director/Board Member, 49
Sector
The sector is a crucial part of any industry, and in the context of healthcare, it's no exception. Healthcare is a broad sector that encompasses various subcategories.
Healthcare services are a vital part of the sector, providing essential care to patients. This can include medical specialties, surgical services, and other forms of patient care.
Healthcare equipment and supplies are also essential components of the sector. Medical equipment, supplies, and distribution are critical for providing quality care to patients.
Diagnostic and testing substances are used to identify and diagnose medical conditions. These substances are a crucial part of the sector, enabling healthcare professionals to provide accurate diagnoses and effective treatment plans.
Here is a breakdown of the sector's subcategories:
Morgan Stanley 23rd Annual Global Healthcare Conference

The Morgan Stanley 23rd Annual Global Healthcare Conference is a significant event in the industry. It brings together top healthcare executives, investors, and analysts to discuss the latest trends and developments.
The conference features presentations from leading healthcare companies, including Amgen, AstraZeneca, and Biogen. These presentations provide valuable insights into the companies' strategies and outlooks.
The event also includes panel discussions and networking opportunities, allowing attendees to engage with industry experts and peers. This exchange of ideas and information is essential for driving innovation and growth in the healthcare sector.
The conference has become a premier platform for healthcare companies to showcase their products and services. In recent years, the event has seen a surge in attendance and participation from both established and emerging players in the industry.
The Morgan Stanley 23rd Annual Global Healthcare Conference is a must-attend event for anyone interested in the healthcare industry. It offers a unique opportunity to stay ahead of the curve and make informed investment decisions.
Readers also liked: Kingstone Companies
Sales and Performance
In 2020, 10x Genomics, Inc. generated $155M in sales from the United States.
The company saw a significant increase in sales in 2021, reaching $258M in the United States.
The United States remained the largest market for 10x Genomics, accounting for 48.4% of total sales in 2021.
Europe, Middle East and Africa contributed $108M to the company's sales in 2021, a notable increase from the $73.26M in 2020.
China's sales decreased from $74.92M in 2021 to $59.56M in 2022, a decline of 20.6%.
The Asia-Pacific region, excluding China, saw a steady increase in sales, reaching $52.29M in 2023.
The Americas, excluding the United States, generated $13.1M in sales in 2023, a notable increase from $8.79M in 2022.
Here's a breakdown of 10x Genomics' sales by region for 2021:
Tools and Technology
The 10x Genomics Chromium Controller is a powerful tool for running assays. It can handle low-throughput (100–1000 cells) and moderate-throughput (1,000–10,000 cells) assays with ease.
One notable feature of the Chromium Controller is its ability to run low-throughput assays. This makes it a great option for researchers who need to analyze small samples.
The moderate-throughput capabilities of the Chromium Controller allow it to handle a larger number of cells, making it a good choice for researchers who need to analyze more extensive samples.
Frequently Asked Questions
What is the controversy with 10x Genomics?
10x Genomics is involved in a patent lawsuit with Vizgen Inc. over allegedly unlawful use of gene sequencing technology developed by Harvard researchers.
What is 10x Genomics known for?
10x Genomics is a leading biotech company known for designing and manufacturing cutting-edge gene sequencing technology for scientific research. Their innovative solutions have revolutionized the field of genomics, enabling new discoveries and insights.
Is 10x Genomics a good stock to buy?
According to the Zacks Rank, 10x Genomics (TXG) is considered a good stock to buy, having been upgraded to a #2 (Buy) rating due to an upward trend in earnings estimates. This suggests a potentially attractive investment opportunity, but further research is recommended.
Featured Images: pexels.com


